The Vanguard Group 13D and 13G filings for Cytek Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-29 11:21 am Sale |
2025-06-30 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 7,765,138 6.130% |
-1,856,870 (-19.30%) |
Filing |
| 2025-04-30 10:57 am Sale |
2025-03-31 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 9,622,008 7.510% |
-2,268,692 (-19.08%) |
Filing |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 11,890,700 8.770% |
4,119,633 (+53.01%) |
Filing |
| 2023-02-09 11:16 am Purchase |
2022-12-30 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 7,771,067 5.760% |
7,771,067 (New Position) |
Filing |